AIMT

ANALYST NOTE: AIMT (Aimmune Therapeutics, Inc.) Date: 2026-06-13 Current Price: $34.49

1. Structural Readiness

Conservative Entry: Not yet defined (awaiting breakout confirmation) Aggressive/Pre-breakout Entry: Current market levels ($34.49) represent a potential entry zone for a forming coil, provided price holds above the structural support line. Extension: Not applicable (price has not yet broken out). Current Price: $34.49 ATR Current: 1.0% (Sub-threshold volatility).

Structural Interpretation:

2. Thesis Layer

Thesis Classification: TACTICAL / Setup-Led Secular Thesis: None. Analysis: As of 2026-06-13, there is no named macro or secular thesis attached to this name in the current context. The investment case must be judged strictly on the quality of the technical setup (the forming coil) and the underlying business fundamentals available at this date. No external narrative or sector-wide tailwind is being assumed. The conviction relies entirely on the structural readiness of the chart and the specific operational milestones recorded in the evidence base.

3. Business Analysis

Company Overview: Aimmune Therapeutics, Inc. is a biopharmaceutical company focused on the development of immunotherapies for food allergies. Business Model: The company operates on a dual-track model:

• Commercialization: Selling approved therapies (specifically Palforzia for peanut allergy) through a specialized distribution network (REMS).
• Pipeline Development: Advancing clinical-stage assets for other food allergies (tree nuts, egg, milk) and novel delivery mechanisms.

Supporting Evidence (As of 2020-07-30, the latest available source date):

• Regulatory Trajectory: Management stated on July 30, 2020, that they received Day 180 questions from the EMA and expected the regulatory review of their marketing authorization application to complete in the fourth quarter of that year.
• Commercial Infrastructure: As of the same date, nearly 1,000 allergists and 600 allergy practices were REMS-certified. Approximately 100 allergists had enrolled patients, with half of those enrolling more than one patient.
• Clinical Data: In the ARC004 study, over 80% of participants at 2 years were able to tolerate a single dose of 2,000 mg of peanut protein (approx. 14 kernels).
• Pipeline Expansion: Management noted the prevalence of tree nut allergy in the US is close in size to peanut allergy, indicating a significant addressable market for future products.
• Insurance Coverage: As of Q2 2020, 39 policies were written, representing approximately 102 million lives.
• Liquidity: The company exited Q2 2020 with $318 million in cash, cash equivalents, and investments.
• Future Milestones: Management expected to start dosing patients in the Phase Ib study early in 2021.

*Note: The evidence base provided is dated 2020. As of the event date of 2026-06-13, there is no evidence provided regarding the commercial performance, revenue realization, or updated clinical status of the company post-2020. The analysis of the business is strictly limited to the state of affairs as recorded in the 2020 transcript.*

4. Archetype and Conviction

Archetype: Growth Leader Fit: The company fits the "Growth Leader" archetype due to its focus on a high-prevalence market (food allergies), a novel therapeutic mechanism (oral immunotherapy), and a clear path to expanding its addressable market from peanuts to tree nuts and other allergens. The business model relies on high-growth potential driven by regulatory approvals and market penetration.

Conviction Stack:

• Thesis Strength: Low (No named secular thesis; purely tactical).
• Evidence Quality: Mixed. The evidence provided (2020) is strong regarding the *potential* and *infrastructure* (cash, REMS network, clinical data), but it is historically dated relative to the 2026 event date. There is a significant gap in current financial performance data.
• Structural Quality: Moderate. The "Forming" coil indicates a stable base, but the sub-threshold ATR (1.0%) suggests a lack of immediate volatility or momentum. The setup is not yet confirmed.
• Rerating Potential: Dependent on the confirmation of the breakout and the resolution of the evidence gap (i.e., actual commercial results post-2020).

Valuation Context: No specific valuation metrics (P/E, P/S, DCF) are provided in the evidence base for 2026. The $318M cash position from 2020 is the only liquidity anchor available, but its relevance in 2026 is unknown without updated balance sheet data.

5. Invalidations, Strengths, and Gaps

What Would Invalidate the Case:

• Confirmation that the company has exhausted its cash runway or failed to commercialize the product effectively (inferred risk given the 2020 cash position vs. 2026 date).
• Regulatory setbacks or loss of REMS certification.

What Would Strengthen the Case:

• Evidence of sustained revenue growth and market penetration post-2020.
• Successful initiation and positive data readouts from the Phase Ib study (expected early 2021) and subsequent trials.

Gaps in the Evidence Base:

• Critical Missing Data: There is no financial or operational evidence between 2020 and 2026. The state of the company's cash, revenue, and clinical progress as of June 2026 is unknown.
• Missing Evidence: No current earnings transcripts, no updated balance sheet, no recent clinical trial results, and no current analyst coverage.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: low Key risks: Evidence base is 6 years old (2020) with no data on current financials or clinical status; Sub-threshold ATR (1.0%) indicates low momentum; No named secular thesis to support conviction. Sizing hint: Minimal position size due to lack of current fundamental data and unconfirmed setup. Expected path: Price consolidates in the forming range; potential breakout if fundamental catalysts emerge; risk of invalidation if support breaks. Expected horizon: Indefinite (dependent on fundamental data release and technical breakout).